Zoetis Inc (ZTS)
176.71
+1.04
(+0.59%)
USD |
NYSE |
Nov 21, 16:00
176.71
0.00 (0.00%)
Pre-Market: 20:00
Zoetis Enterprise Value: 84.59B for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 84.59B |
| November 20, 2024 | 84.12B |
| November 19, 2024 | 84.07B |
| November 18, 2024 | 84.46B |
| November 15, 2024 | 83.88B |
| November 14, 2024 | 83.65B |
| November 13, 2024 | 84.74B |
| November 12, 2024 | 83.35B |
| November 11, 2024 | 84.34B |
| November 08, 2024 | 84.64B |
| November 07, 2024 | 83.48B |
| November 06, 2024 | 81.73B |
| November 05, 2024 | 83.94B |
| November 04, 2024 | 83.90B |
| November 01, 2024 | 86.95B |
| October 31, 2024 | 85.52B |
| October 30, 2024 | 87.38B |
| October 29, 2024 | 86.72B |
| October 28, 2024 | 87.39B |
| October 25, 2024 | 86.15B |
| October 24, 2024 | 86.82B |
| October 23, 2024 | 90.20B |
| October 22, 2024 | 90.44B |
| October 21, 2024 | 90.41B |
| October 18, 2024 | 92.14B |
| Date | Value |
|---|---|
| October 17, 2024 | 91.11B |
| October 16, 2024 | 92.66B |
| October 15, 2024 | 91.74B |
| October 14, 2024 | 91.86B |
| October 11, 2024 | 90.69B |
| October 10, 2024 | 90.78B |
| October 09, 2024 | 90.74B |
| October 08, 2024 | 89.47B |
| October 07, 2024 | 89.43B |
| October 04, 2024 | 90.67B |
| October 03, 2024 | 91.11B |
| October 02, 2024 | 91.77B |
| October 01, 2024 | 92.65B |
| September 30, 2024 | 93.09B |
| September 27, 2024 | 93.24B |
| September 26, 2024 | 93.27B |
| September 25, 2024 | 91.76B |
| September 24, 2024 | 92.74B |
| September 23, 2024 | 92.69B |
| September 20, 2024 | 92.26B |
| September 19, 2024 | 92.53B |
| September 18, 2024 | 94.00B |
| September 17, 2024 | 93.65B |
| September 16, 2024 | 92.99B |
| September 13, 2024 | 91.56B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
48.55B
Minimum
Mar 23 2020
120.20B
Maximum
Dec 29 2021
83.86B
Average
83.30B
Median
Aug 09 2022
Enterprise Value Benchmarks
| Pfizer Inc | 199.35B |
| Regeneron Pharmaceuticals Inc | 74.00B |
| Vertex Pharmaceuticals Inc | 109.46B |
| Alnylam Pharmaceuticals Inc | 30.08B |
| Biomarin Pharmaceutical Inc | 11.76B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 682.00M |
| Revenue (Quarterly) | 2.388B |
| Total Expenses (Quarterly) | 1.468B |
| EPS Diluted (Quarterly) | 1.50 |
| Gross Profit Margin (Quarterly) | 70.64% |
| Profit Margin (Quarterly) | 28.56% |
| Earnings Yield | 3.01% |
| Operating Earnings Yield | 4.13% |
| Normalized Earnings Yield | 3.167 |